A new series of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridine compounds have been discovered as potent anaplastic lymphoma kinase (ALK) inhibitors. The 4-hydroxyphenyl in the 6-position of 1H-pyrazolo[3,4-b]pyridine were crucial and a fluorine atom substitution could give promising inhibitory activity. The IC of compound 9v against ALK was up to 1.58 nM and a binding mechanism was proposed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2019.01.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer.
Cell Death Dis
December 2024
Astbury Centre for Structural Molecular Biology and School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK.
The fusion event between EML4 and ALK drives a significant oncogenic activity in 5% of non-small cell lung cancer (NSCLC). Even though potent ALK-tyrosine kinase inhibitors (ALK-TKIs) are successfully used for the treatment of EML4-ALK-positive NSCLC patients, a subset of those patients eventually acquire resistance during their therapy. Here, we investigate the kinase responses in EML4-ALK V1 and V3-harbouring NSCLC cancer cells after acute inhibition with ALK TKI, lorlatinib (LOR).
View Article and Find Full Text PDFSynthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer.
Eur J Med Chem
February 2025
Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, PR China. Electronic address:
EGFR and ALK are common driver genes in NSCLC, and more patients with these mutations are being identified due to medical advances. Thus, developing dual-target EGFR/ALK inhibitors is crucial. In this study, 10 novel small molecules were designed and synthesized.
View Article and Find Full Text PDFFinal Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.
J Thorac Oncol
November 2024
Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore.
Article Synopsis
- Lorlatinib is a third-generation drug that effectively targets ALK and ROS1 tyrosine kinases in patients with advanced ALK-positive non-small cell lung cancer (NSCLC), showing promising long-term survival rates.
- The study involved 367 adults with varying treatment backgrounds who took lorlatinib daily and assessed response rates, overall survival (OS), and safety.
- Results indicated that patients had substantial improvements in OS across different treatment groups, with noted adverse events leading to dose adjustments in some cases, but the drug's safety profile remained generally stable over five years of follow-up.
Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells.
Endocrine
November 2024
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Article Synopsis
- * In vitro tests show that doxorubizen has a significantly stronger effect on reducing cell growth, inducing apoptosis, and inhibiting migration in ATC cells than doxorubicin and lenvatinib alone.
- * The findings indicate that doxorubizen not only works effectively on its own but also enhances the effects of lenvatinib, suggesting potential for future clinical trials in ATC patients.
Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.
Head Neck
October 2024
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Background: The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments.
Methods: We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed-carboplatin (PC) at Mayo Clinic since 2019.
Results: Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!